A Biosimilar medicine is a
Introduction
In Singapore, generic version of biopharmaceuticals is specified as "similar biological products". The Central Regulatory Authority in Singapore for approval of a product is Health Science Authority (HAS). The Guidance document for similar biological products is adapted mainly from the EMEA guidelines. (1) Biosimilar products are required to go through a scientifically rigorous pathway based on a stepwise head to head comparability to the RBP in terms of quality of product (physical and chemical characteristics), nonclinical studies (toxicity, functionality) and clinical studies (safety, efficacy & immunogenicity). The comparability is designed to show similarity and demonstrate that there are no clinically meaningful differences between the RBP and biosimilar product.
A biosimilar product may ride on the safety and efficacy of the RBP to obtain approval for one or more indications approved for the RBP without head-to-head comparison in clinical studies for each indications. This is based on the overall evidence taking into account the physicochemical similarity demonstrated through analytical and functional assays (structure, molecular weight, binding assays, etc) that the biosimilar works in the same way as the RBP, as well as clinical studies conducted in the most sensitive clinical setting which allows the bridging of the efficacy and safety to other indications. (2)
Definition
A biosimilar product is a biological therapeutic product demonstrated to be similar, in physicochemical characteristics, biological activity, safety and efficacy to an existing registered biological product. (3)
Reference product
• It must be a Singapore biological reference product.
• The active substance(s) of the bio similar product and reference product should be similar in molecular and biological terms. 
Application Types
The product must have been approved by at least one of the following reference agencies: EU EMA, Australia TGA (Therapeutic Goods Administration), US FDA (Food Drug Administration) and Health Canada.
Bio similar products are eligible for the (New Drug Application) NDA-2 and NDA-3 application types. When selecting the Product Type in Pharmaceutical Regulatory & Information System (PRISM) section 3.2, select "Biological Drug". (4) NDA-2: For the first strength of a bio similar product with the same dosage form and route of administration as the reference biological product. NDA-3: For subsequent strength(s) of a bio similar product that has been registered or has been submitted as an NDA-2. The product name, pharmaceutical dosage form, indication, dosing regimen and patient population shall be the same as that for the NDA-2. (4)
Format
International Common Harmonization Common Technical Document (ICH CTD) or ASEAN Common Technical Document (ACTD) format. Testing Laboratory: Certificates of analysis from a laboratory in one of HAS"s reference agencies or other accredited biologics testing laboratory. Table 1 Timeline requirements in product submission in Singapore
Timelines

S. No
Requirements Timeline 1.
The complete dossier should be submitted after the PRISM application submission.
2 working days
2.
Submit full information after issuance of screening query letter 30 calendar days 3.
Reporting of Serious Adverse Drug Reactions (ADR) & nonserious ADRs 15 days
4.
Product licence holder is required to submit the global PSURs to HSA 6 months for the first 2 years; Yearly for the following 3 years.
Fees:
The fee structure and quanta are subject to ongoing review.
Screening fee:
The screening fee per application is payable at the time of PRISM submission. The screening fees are nonrefundable once the application has been successfully submitted via PRISM.
Evaluation fee: Evaluation fees are payable upon acceptance of the dossier for evaluation. The evaluation fees are nonrefundable once the application is accepted, regardless of the final decision by Health Science Authority (HAS). The progressive payment scheme was implemented to allow payment of evaluation fees by installments. This is an optional opt-in payment scheme catered for companies who are under the GIRO payment scheme. It is applicable to similar biological Products. For applicants that had chosen the progressive payment scheme, in the event of an application withdrawal at any point in time during the evaluation stage, any fees that had been charged, but not yet collected, would still have to be paid; all evaluation fees that had been paid are non-refundable. (5)
Change in evaluation fees
Changes in the evaluation fees may occur if there are changes to the application type:
• Change of Application within the Same Application Type.
• Change of Application between Different Application Types. (5) 
GMP Audit
Site Audit:
Describes purpose of the visit and scope of activities and update the recent changes.
Review past non-conformities 3.
Documentary review:
Review all batch records, analytical records, GMP training records, validation documents, product complaints, records of self-inspection.
Wrap-up meeting and classify Nonconformities into major or minor etc.
4.
Post Audit:
A letter should be sent to manufacturer to obtain his response to the non-conformities observed.
If the audit team is satisfied with the CA and time frames for rectification, the audit will be "closed out" Application for a bio similar product is to be submitted as a new drug application (NDA) via the abridged dossier evaluation route.
Submission
Post Approval Process
The steps to submit an MAV or MIV is similar to submitting an NDA as seen in the above figure.
There are two types of variation applications: Major Variation Application (MAV) and Minor Variation Application (MIV). For similar biological products, MAV-1 is applicable. (7): 
Documentary Requirements
Post Approval Batch Requirements
Bio similar products are subjected to a risk-based post-approval batch release programme. Prior to import and sale of each batch of the bio similar product, should submit:
 Manufacturer"s batch release data and certificate of analysis.  A letter of commitment to provide yearly stability data on annual stability batch.
Post Approval Requirements
There are two types of variation applications: Major Variation Application (MAV) and Minor Variation Application (MIV). For similar biological products, MAV-1 is applicable.
MAV-1 (8)
Any variation to the approved indication(s), dosing regimen(s), patient group(s), and/or inclusion of clinical information extending the usage of the product. 
Conclusion
As Biosimilar are immunogenic. This may cause antibodies in the patient"s body to attack and neutralize the biosimilar and it could have serious consequences. Regulations and laws should address multiple areas, going beyond just the regulatory approval process, pharmacovigilance systems and prescription practices are adapted. Quality, Non-Clinical, Clinical Studies guidelines taken from European Medicine Agency. I Conclude:
 In Singapore, evaluation routes for Biosimilar are through NDA-2 and NDA-3.  PRISM Application is most needed for any product submission in Singapore.  Clinical Trial Certification (CTC) is made through Online.  For Similar Biological products, Major Variation Application (MAV-1) is applicable.
